Roundtable Discussion: Novel Oral Anti-Coagulants (NOACs)

Published: 03 September 2015

  • Views:

    Views Icon 193
  • Likes:

    Heart Icon 0

Overview

Full programme

  • Views:

    Views Icon 193
  • Likes:

    Heart Icon 0

Overview

On November 12th 2014, Radcliffe Cardiology, in association with the Arrhythmia & Electrophysiology Review (AER) journal, filmed a roundtable discussion entitled 'Novel Oral Anti-Coagulants (NOACs): Hot Topics & Current Issues' in London, UK.

The discussion was moderated by Professor A. John Camm (London, UK), a renowned authority in anticoagulation and atrial fibrillation, and an editorial board member of AER. He was joined by expert group of physicians including Doctor Marco Alings (Breda, NL), Professors Raffaele De Caterina (Chieti, IT), Paulus Kirchhof (Birmingham, UK), Jean-Yves Le Heuzey (Paris, FR) and Freek Verheugt (Amsterdam, NL).

The meeting comprised of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants in various clinical scenarios.

This educational activity is intended for an international audience of non-US healthcare professionals, specifically electrophysiologists and cardiologists. However, neurologists, internal medicine specialists, primary care physicians, and other healthcare professionals involved in the diagnosis and management of patients with atrial fibrillation (AF) will also find this topical.

The CME e-learning modules can be accessed here. This course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 CME credit hour.

On 12 November 2014, Radcliffe Cardiology, in association with Arrhythmia & Electrophysiology Review (AER) journal, held a roundtable discussion in London, UK. The discussion held between an expert group of physicians was moderated by Professor A John Camm, a renowned authority in anticoagulation and atrial fibrillation. The meeting comprised a series of seven presentations and subsequent panel discussions on a range of topical issues related to the use of non-vitamin K antagonist (novel) oral anticoagulants (NOACs): real-world versus clinical trial data; once or twice daily dosing regimens; spot checks or monitoring for anticoagulation status; antidotes for NOACs; NOACs and dual antiplatelet therapy; NOAC treatment in chronic renal impairment; and choosing between NOACs. This paper summarises the presentations and presents key highlights from the subsequent discussions.

The Novel Oral Anti-Coagulants (NOACs): Hot Topics & Current Issues roundtable was supported by an unrestricted educational grant by Daiichi-Sankyo

Panellists

  • A. John Camm, Professor of Clinical Cardiology and Head of the Department of Cardiac and Vascular Sciences, St. George's Hospital Medical Centre, London, UK
  • Marco Alings, Director of the Cardiology Training Program, Amphia Ziekenhuis, Breda, The Netherlands
  • Raffaele De Caterina, Professor of Cardiology and Director of the University Cardiology Division, "G. d'Annunzio" University, Chieti, Italy
  • Paulus Kirchhof, Chair in Cardiovascular Medicine Cardiovascular and Respiratory Sciences, University of Birmingham, UK
  • Jean-Yves Le Heuzey, Professor of Cardiology and Head of the Arrhythmia Department, Georges Pompidou Hospital, Paris, France
  • Freek Verheugt, Chairman, Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands

Key Learning Objectives

  • To review the established evidence-base for non-VKA thromboprophylaxis in atrial fibrillation (AF)
  • o consider recent and emerging data on non-VKA oral anticoagulants in AF trials and registries
  • To discuss on-going non-VKA oral anticoagulant research in patients with AF
  • To identify and refine the indications for specific non-VKA oral anticoagulants in AF
  • To establish the nature of further non-VKA oral anticoagulant research needed for new AF indications

Series overview

Part 1

SESSION 1

1 session

  • REAL WORLD VERSUS CLINICAL TRIAL DATA WITH NOACS

    Watch now

Part 2

SESSION 2

1 session

Part 3

SESSION 3

1 session

  • SPOT CHECKS OR MONITORING OF NOACS FOR ANTICOAGULATION STATUS

    Watch now

Part 4

SESSION 4

1 session

Part 5

SESSION 5

1 session

  • NOACS AND DUAL ANTIPLATELET THERAPY

    Watch now

Part 6

SESSION 6

1 session

  • NOAC TREATMENT IN CHRONIC RENAL IMPAIRMENT

    Watch now

Part 7

SESSION 7

1 session

Faculty biographies